During the past decade, Emad Ibrahim, MD, Inc. conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 9 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 9 clinical trials were completed. i.e. 128.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Emad Ibrahim, MD, Inc." #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Spectrum Pharmaceuticals, Inc" with 2 trials sponsored, "Takeda" with 2 trials sponsored, "Agios Pharmaceuticals, Inc." with 1 trials sponsored and "BeyondSpring Pharmaceuticals Inc." with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Emad Ibrahim, MD, Inc." #1 collaborator was "Bristol-Myers Squibb" with 2 trials as a collaborator, "George Clinical Pty Ltd" with 1 trials as a collaborator, "Takeda Development Center Americas, Inc." with 1 trials as a collaborator and "The Physicians' Services Incorporated Foundation" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Emad Ibrahim, MD, Inc." are "Breast Cancer" (2 trials), "Metastatic Breast Cancer" (2 trials), "Neutropenia" (2 trials), "Chemotherapy-induced Nausea and Vomiting" (1 trials) and "Chemotherapy-induced Neutropenia" (1 trials). Many other conditions were trialed in "Emad Ibrahim, MD, Inc." in a lesser frequency.

Most popular intervention types in "Emad Ibrahim, MD, Inc." are "Drug" (14 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Pegfilgrastim" (3 trials), "Cyclophosphamide" (2 trials), "Docetaxel" (2 trials) and "Fulvestrant" (2 trials). Other intervention names were less common.

The vast majority of trials in "Emad Ibrahim, MD, Inc." are 13 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Emad Ibrahim, MD, Inc.". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Emad Ibrahim, MD, Inc., undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Emad Ibrahim, MD, Inc., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".